Olga Y. Baikova

Olga Y. Baikova

Auto-generated profile, based on publicly available information

Olga Y. Baikova

Federal State Autonomous Scientific Institution “Chumakov Federal Center for Research and Development of Immune‐and‐Biological Products of the Russian Academy of Sciences” (Institute of Poliomyelitis) (FSASI Chumakov FSC R&D IBP RAS [Institute of poliomyelitis]) Moscow Russia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2025 in Journal of Medical Virology
Verified
Journal Article
Closed access
ASArmen K. Shakaryan
Armen K. Shakaryan
YMYulia M. Mikhailova
Yulia M. Mikhailova
ACAlina V. Chirova
Alina V. Chirova
ECEvgeniya A. Cherepanova
Evgeniya A. Cherepanova
OBOlga Y. Baikova
Olga Y. Baikova
OIOlga Ivanova
Olga Ivanova

31 October 2026 in Problems of Virology
Verified
Journal Article
Open access
PDF file
EKEvgenia Karpova
Evgenia Karpova
КВКарпова Евгения Викторовна
Карпова Евгения Викторовна
БЮБайкова Ольга Юрьевна
Байкова Ольга Юрьевна
OBOlga Yu. Baikova
Olga Yu. Baikova
ЗДЗолотарева Анастасия Дмитриевна
Золотарева Анастасия Дмитриевна
LKLiubov Kozlovskaya
Liubov Kozlovskaya
Introduction. The Global Polio Eradication Initiative strategy, along with vaccination and epidemiological surveillance efforts, includes measures to reduce the risk of poliovirus (PV) spread from laboratories and vaccine production facilities (containment). Due to containment requirements, studies to determine immunity to PV types 1–3 necessary for achieving program goals are limited for most laboratories, primarily for PV type 2. To replace the Sabin strains 1–3 typically used in the neutralization assay, genetically modified S19S strains 1–3 were developed. These strains retain the antigenic properties of the Sabin strains but exhibit a higher degree of attenuation and genetic stability. The objective of this study is to compare S19S strains 1–3 for use in the neutralization assay in cell culture to assess the levels of type-specific antibodies to PV types 1–3 and to determine the validation parameters for the method. Materials and methods. The study was conducted using the neutralization test in HEp2c cell using the standard WHO-recommended method at 36.5 °C for Sabin strains types 1–3 and at 33 °C for S19S strains types 1–3, using a set of reference sera and 50 sera from polio-vaccinated children. Results. Data from three independent experiments showed a high correlation between the neutralizing antibody titers obtained using S19S strains types 1–3 and the control Sabin strains types 1–3 (R 0.9). The repeatability and intermediate (intralaboratory) precision of the assay were also high (CV 10%). Conclusion. S19S strains 1–3 can be used as a replacement for Sabin strains 1–3 when performing a neutralization test in HEp2c cells to assess the level of type-specific antibodies to PV.